These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 8540311

  • 1. Serum pepsinogen values as possible markers for evaluating the possibility of peptic ulcer recurrence under H2-blocker half-dose maintenance therapy.
    Matsushima M, Miki K, Ichinose M, Kakei N, Yahagi N, Kido M, Shimizu Y, Ishihama S, Tsukada S, Kurokawa K.
    Adv Exp Med Biol; 1995; 362():131-7. PubMed ID: 8540311
    [No Abstract] [Full Text] [Related]

  • 2. Helicobacter pylori infection and serum pepsinogen I concentration in peptic ulcer patients: effect of bacterial eradication.
    Park SM, Park J, Chang SK, Yoo BC, Kim HJ.
    Korean J Intern Med; 1996 Jan; 11(1):1-8. PubMed ID: 8882471
    [Abstract] [Full Text] [Related]

  • 3. Increased serum pepsinogen I and recurrence of duodenal ulcer.
    Sumii K, Inbe A, Uemura N, Kimura M, Haruma K, Yoshihara M, Teshima H, Kajiyama G, Miyoshi A.
    Scand J Gastroenterol; 1989 Dec; 24(10):1200-4. PubMed ID: 2574906
    [Abstract] [Full Text] [Related]

  • 4. [Peptic ulcer: current therapy].
    Pieragnoli E.
    G Clin Med; 1987 Apr; 68(4):197-209. PubMed ID: 2886387
    [No Abstract] [Full Text] [Related]

  • 5. Serum group I pepsinogens by radioimmunoassay in control subjects and patients with peptic ulcer.
    Samloff IM, Liebman WM, Panitch NM.
    Gastroenterology; 1975 Jul; 69(1):83-90. PubMed ID: 1150038
    [Abstract] [Full Text] [Related]

  • 6. [The medical therapy of peptic ulcer. The state of the art].
    Perroni GB, De Matteis G, Pellizzeri F, Cassone A, Malara F.
    Minerva Chir; 1992 Apr 15; 47(7):607-12. PubMed ID: 1350332
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Clinical, secretory, radiological and endoscopic evolution of patients with gastroduodenal ulcer treated with Ulcosilvanil, as compared with those treated with histamine H2 receptor antagonists].
    Contraşiu P, Calinici V.
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1980 Apr 15; 32(4):359-63. PubMed ID: 6113650
    [No Abstract] [Full Text] [Related]

  • 10. [Current aspects of course treatment and secondary prevention of peptic ulcer].
    Ryss ES.
    Klin Med (Mosk); 1990 Apr 15; 68(4):134-42. PubMed ID: 1973467
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Future trends in the management of peptic ulcer disease.
    Misiewicz JJ.
    Scand J Gastroenterol Suppl; 1988 Apr 15; 146():175-84. PubMed ID: 2906462
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.